Skip to content

#United States

19 NovThu
  1. Marijuana Moment (psychedelics policy only)42

    US House veterans committee holds hearing on psychedelic therapies for military veterans

    A US House Veterans' Affairs health subcommittee held a Wednesday hearing on veterans' access to psychedelic-assisted therapies, with VA officials and researchers testifying. The VA's Andrew Gradison said the department is running 21 active clinical studies on psychedelics, including an August-announced psilocybin trial in veterans with treatment-resistant depression.

17 NovTue
  1. Marijuana Moment (psychedelics policy only)40

    US House Veterans' Affairs health subcommittee to hold hearing on psychedelic-assisted therapies for veterans

    The House Veterans' Affairs Subcommittee on Health will hold a Wednesday hearing titled "Psychedelic-Assisted Therapies for Veterans: The Path Forward," with VA officials, medical professionals and researchers testifying. A VA official's written testimony says the department is conducting 21 active clinical studies on psychedelics, including a trial announced in August on psilocybin for veterans with treatment-resistant depression.

14 NovSat
  1. The Microdose (UC Berkeley BCSP)62

    FDA said to end priority voucher program as Compass Pathways files psilocybin application

    Reuters reported that the US Food and Drug Administration is ending the Commissioner's National Priority Voucher program, which had compressed a 10-12 month drug review to 1-2 months. Three psychedelics-related voucher holders are affected, including Compass Pathways' COMP360 for treatment-resistant depression, Usona Institute's psilocybin for major depressive disorder and Transcend Therapeutics' methylone for PTSD.

13 NovFri
  1. Psychedelic Alpha48

    HHS taps Mark Cuban's company to develop ibogaine for PTSD and commits $20M for real-world evidence network

    The U.S. Department of Health and Human Services said it will tap Mark Cuban's company to develop ibogaine for post-traumatic stress disorder and commit $20 million to a real-world evidence network. HHS Secretary RFK Jr. gave the update at a press conference, where VA Senior Advisor Andrew Gradison stood in for VA Secretary Doug Collins.

10 NovTue
  1. Federal Register: DEA and FDA documents (US)40

    DEA proposes 2027 production quotas for Schedule I and II controlled substances and list I chemicals

    The US Drug Enforcement Administration has proposed 2027 aggregate production quotas for Schedule I and II controlled substances and an assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine and phenylpropanolamine. Written comments are due by December 10, 2026, under Docket No. DEA-1730P, after which the Administrator will publish a final order.

9 NovMon
  1. Psychedelic Alpha80

    Compass Pathways submits COMP360 psilocybin new drug application to FDA for treatment-resistant depression

    Compass Pathways announced it has submitted a new drug application to the FDA for its COMP360 psilocybin for treatment-resistant depression (TRD). The FDA is now reviewing three psychedelic applications, after Resilient Pharmaceuticals resubmitted its MDMA for PTSD application this summer and Usona Institute filed its psilocybin for major depressive disorder (MDD) package more recently. Compass said its package includes data from more than 1,000 participants, and the company is targeting an H1 2027 launch.

    Why it matters: With three psychedelic applications now before the FDA, the agency's next steps on COMP360 will show how it handles a package drawn from more than 1,000 participants.

5 NovThu
2 NovMon
  1. ClinicalTrials.gov: newly registered trials60

    NYU Langone registers trial of psilocybin-assisted psychotherapy for fear of cancer recurrence in early-stage breast cancer

    NYU Langone Health has registered a double-blind, parallel-design, placebo-controlled, two-centre randomised controlled trial of single-dose psilocybin-assisted psychotherapy in 100 outpatients with early-stage breast cancer. The trial is designed to evaluate efficacy and psychological mechanisms for fear of cancer recurrence (FCR), anxiety and depression distress and quality of life, comparing a single 25mg oral dose of psilocybin with a single 5mg oral dose as an active placebo, both delivered with a psychotherapy platform.

    Why it matters: The registry record sets out a two-centre design with an active placebo, so readers can see how the trial plans to separate psilocybin from expectancy in fear of cancer recurrence.

30 OctFri
  1. Europe PMC: new psychedelic research papers55

    Psilocybin with psychological support for anhedonia in treatment-resistant depression: a randomised controlled pilot trial

    A randomised, double-blind, placebo-controlled pilot trial in 20 participants with treatment-resistant major depressive disorder found no statistically significant between-group difference in anhedonia at the primary week 1 endpoint, with a DARS change difference of 11.2 (95% CI, -1.0 to 23.3; p = 0.073) for psilocybin 25 mg versus 1 mg, both given with psychological support.

29 OctThu
  1. Lucid News58

    US federal health officials outline pre-approval groundwork for psychedelic medicines

    Officials from HHS, the FDA, the VA and ARPA-H described at The Psychedelic Healthcare Forum on Oct. 15 how an April executive order has reshaped federal preparation for psychedelic medicines. HHS Deputy General Counsel Matt Zorn said the order does not change statutory or regulatory standards, while the VA has designated 10 medical centres as Phase 1 lead sites and estimated around 100,000 veterans would qualify for psychedelic-assisted therapy immediately upon approval. The FDA's Dr Valentina Mantua said the agency oversees approximately 433 Investigational New Drug applications and has already requested REMS proposals from developers, and ARPA-H's Dr Al Bugazia cited cardiotoxicity and QTc prolongation risks, the lack of a domestic GMP manufacturer and a DEA manufacturing quota of just over 200 grams as obstacles for ibogaine research.

23 OctFri
  1. The Microdose (UC Berkeley BCSP)44

    ICER to review Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depression

    The Institute for Clinical and Economic Review announced on Wednesday it will evaluate the clinical effectiveness and cost of Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depression, with results to be discussed at the May 2027 meeting of the New England Comparative Effectiveness Public Advisory Council.

22 OctThu
15 OctThu
9 OctFri
  1. Lucid News63

    New Mexico health department draft psilocybin rules draw rebuke at public hearing

    Medical providers, veterans, legal experts and the legislative sponsor of New Mexico's Medical Psilocybin Act criticised draft rules 7.35.3 and 7.35.2 NMAC at an Oct. 2 public hearing before the New Mexico Department of Health, arguing the proposed prescriber gateway, landlord consent requirements and staffing ratios exceed the statute and could block access. The department is accelerating the program's launch to December 2026, a year ahead of the statutory deadline. Speakers said the rules would require an in-person exam with a certifying clinician, patient identification cards and up to 30 days of state review, and that landlord sign-off for homebound patients and leased healing centres conflicts with fair housing law; some clinical educators praised the draft training and supervision standards. Sixteen advocacy and clinical organisations have asked Rep. Nathan P. Small to add $500,000 for the Treatment Equity Fund and $500,000 for University of New Mexico palliative research.

5 OctMon
  1. FDA: press announcements (US)62

    FDA seeks public input on early-phase ibogaine trial design

    The US Food and Drug Administration has issued a request for information on approaches it is considering for the design of early-phase clinical trials of ibogaine drug products, and is seeking public comment.

    Why it matters: The request sets out the protocol questions the agency wants answered, including a starting dose cap, so researchers and sponsors can see what evidence the FDA expects before early-phase ibogaine trials proceed.

30 SepWed
  1. MAPS62

    MAPS opposes DEA proposal to place five tryptamines in Schedule I

    MAPS has stated its opposition to a DEA proposal to place five little-known psychedelic compounds, 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT, in Schedule I of the Controlled Substances Act. The organisation says this is the agency's second attempt at the same scheduling action, after an earlier version was withdrawn in 2022 following pushback from researchers and legal advocates.

23 SepWed
18 SepFri
22 AugSat
15 AugSat
11 AugTue
  1. MAPS62

    MAPS responds to report that Resilient has resubmitted its MDMA therapy NDA to FDA

    MAPS said it welcomed a new FDA evaluation after an August 9 report by Psychedelic Alpha that Resilient Pharmaceuticals (formerly MAPS PBC and Lykos Therapeutics) had resubmitted its new drug application for MDMA-assisted therapy for PTSD. The resubmission follows the Complete Response Letter issued on August 9, 2024, which recommended additional research on durability of response, safety characterisation and steps to minimise potential bias, and MAPS noted it comes without a new Phase 3 study. MAPS, which funded the clinical research completed in 2022 and says it has no active role in Resilient's drug development, also pointed to the FDA's final July 2026 guidance, Psychedelic Drugs: Considerations for Clinical Investigations, as reflecting approaches it developed with the agency.

16 JulThu